There are so many variables involved, regarding combo versus mono (the true end game goal) use, GvHD applications (which are looking very promising and they just received ODD from FDA for this), and also autoimmune/cancer possibilities being pursued as well, potential for bidding war, potential reverse split as a way to up-list and get off the OTC, dilution, etc....
My opinion is minimum 2-3/share, others have speculated anywhere from 6-8, all the way up to 15. The further they get to mono therapy P3 completion and FDA approval the higher the sale price, but it is widely believed that management has no intention of taking Pro 140 over the finish line without a BO or partner...
For some excellent info, look at Saltz and Blackdoggie comments on the CYDY board. Those guys know way more than myself!
News 
Market Data 
Discover 
